December 1^st, 2024 -- The investigator meeting of the phase III study in nasopharyngeal carcinoma for YL201, (a B7-H3 targeted antibody-drug conjugate), was held in Guangzhou, China. More than 70 experienced oncology experts from over 60 clinical sites (including many top oncologists from major academic cancer institutions across the country) attended the meeting to review and discuss the cutting-edge ADC technology in the treatment of nasopharyngeal carcinoma. The entire meeting was filled with an atmosphere of passion and a spirit of collaboration. YL201, a targeted antibody-drug conjugate is based on MediLink's TMALIN® platform and has received significant attention.

Dr. Tony Xue, founder and chairman of MediLink, and Professor Li Zhang, the leading investigator of the YL201 program, led the meeting. Dr. Tony Xue warmly welcomed and thanked the study investigators from all over the country and highlighted the scientific value of the study in treating patients with nasopharyngeal carcinoma who don’t have many viable options. There was a call to action that YL201 could be a new treatment option in the near future to benefit more NPC patients.

Professor Li Zhang Li chaired the meeting. He pointed out the limitation of current chemotherapy options for nasopharyngeal carcinoma and emphasized the urgent need for more effective treatment options. YL201, has shown promisingefficacy and safety in some early-phase human clinical trials, especially for nasopharyngeal carcinoma and some other solid tumors.

Dr. Jiaqiang Cai, co-founder and CSO of MediLink, shared MediLink’s proprietary TMALIN® technology platform. The TMALIN® platform technology, Tumor Microenvironment Activable LINker-payload (TMALIN®), is a novel ADC platform technology with independent intellectual property rights owned by MediLink. It utilizes a dual cleavage mechanism in the extracellular tumor microenvironment and intracellular lysosome, and possesses characteristics of high-water solubility, high DAR uniformity, high plasma stability, and tumor tissue enrichment.

During the meeting, Professor Hongyun Zhao, Deputy Director of the Clinical Research Department at Sun Yat-sen University Cancer Center, shared the results of the Phase II study of YL201. Given the efficacy and safety data demonstrated for YL201, there is strong rationale for the initiation of a pivotal Phase III clinical study of YL201 to further evaluate efficacy and safety compared to physician selected chemotherapy regimens (when treating patients with recurrent or metastatic nasopharyngeal carcinoma) who have previously failed PD-(L)1 inhibitors and at least second-line chemotherapy.

Welcome by Dr. Tony Xue, Chairman and CEO of MediLink Therapeutics

Presentation by Professor Li Zhang, Chairman of the Investigator Meeting

Dr. Jiaqiang Cai, CSO of MediLink, Introduces the Company's Technology Platform

Dr. Steve Chin, CMO of MediLink Therapeutics, Introduces the Company's Overview

Professor Hongyun Zhao Shares the Results of YL201 Phase II Clinical Trial

Dr. Xian Zhang Reviews the Study Protocol details for the YL201 Phase III Clinical Trial